Fatigue severity across early patients with arthritis with different diagnoses at disease onset (A) and over 3 years of disease (B). Fatigue severity across.

Slides:

Advertisements

Similar presentations

Immunohistochemical (IHC) staining for CD68/CD21 and CD3/CD20 on synovial tissue (ST) of patients with inflammatory bowel disease (IBD) with onset of peripheral.

Advertisements

Summary of TB cases across indications and trial periods

Figure 1 Rheumatoid arthritis development over time in relation to the level of inflammation Figure 1 | Rheumatoid arthritis development over time in relation.

Multivariable model of abatacept retention by RF and anti-CCP status in biologic-naïve patients with or without radiographic erosion at baseline. Multivariable.

Patients included in linear extrapolation and observed/last observation carried forward analyses at week 48. Patients who were rescued or discontinued.

Nat. Rev. Rheumatol. doi: /nrrheum

Immunohistochemical (IHC) staining for CD117 on synovial tissue (ST) of patients with inflammatory bowel disease (IBD) with onset of peripheral arthritis.

Main fields of interest.

Conversion to ACPA and RF seronegative status in patients with early RA treated with abatacept+MTX compared with MTX alone. Conversion to ACPA and RF seronegative.

Changes in evaluation indicators from baseline to 12 weeks per visit.

Kaplan-Meier survival plots for survival without: (A) progression to RA according to the number of joints with significant synovitis defined by GS≥ grade.

Percentage of patients achieving EULAR response

PPD status of CZP-treated patients with RA in the pooled RA safety database (N=4049) at baseline and TB incidence by INH treatment. †One patient who developed.

Patient disposition through 48 weeks in RA-BEYOND

Frequency of patients in flare at each time point over 3 months

Cumulative incidence of tuberculosis (TB) in certolizumab pegol (CZP)-treated patients with rheumatoid arthritis (RA) in the pooled RA safety database.

The severity of fatigue over 8 years of disease in early rheumatoid arthritis patients. The severity of fatigue over 8 years of disease in early rheumatoid.

OR for baseline predictors of MDA at weeks 12, 24, 48, 96 and 144 by univariate analysis of observed data. OR for baseline predictors of MDA at weeks 12,

Pathogenesisof PsA and RA

Fig. 1 Anti-LtxA antibody concentrations in various patient groups.

Box plot of HAQ-DI scores at baseline, week 96 and week 144 categorised by baseline PsA duration. Box plot of HAQ-DI scores at baseline, week 96 and week.

(A) Reduction of circulating stromal cell-derived factor (SDF)-1 levels over time in patients with rheumatoid arthritis (RA) and ankylosing spondylitis.

Box plot showing median cytokine levels and IQRs for (A) IP-10, (B) TNF-α, (C) LT-α and (D) IFN-γ in controls and pSS fatigue groups. Box plot showing.

Relationships between the baseline disease activity scores and scintigraphic sum scores for the patients with RA, pSpA and axSpA. Relationships between.

Different treatment strategies in rheumatoid arthritis in relation to radiographic progression (A) number of swollen joints (B) and fatigue severity over.

Bold diamonds are the mean percentage of time with inactive disease during the first 12 months within the subgroup. Bold diamonds are the mean percentage.

Probability plots JSN score at baseline (A), 10 years (B) and progression (C) for the different age groups (darkest dots: group

Levels of participation in the Psoriatic Arthritis Impact of Disease (PsAID) development process. Levels of participation in the Psoriatic Arthritis Impact.

EULAR-defined characteristics describing arthralgia at risk for RA

The association between alcohol consumption and the severity of MRI-detected inflammation in hand and foot joints of (A) patients with RA and (B) asymptomatic.

Matrix risk model showing the probability of SRP in patients with moderate disease activity after 3 years of MTX treatment. Matrix risk model showing the.

Multivariate analysis for SRP after 3 years in patients with moderate disease activity despite MTX treatment. Multivariate analysis for SRP after 3 years.

Patient-reported adherence towards different IMID treatments in RA (A), PsA (B) or AS (C). Patient-reported adherence towards different IMID treatments.

Clinical response in patients with early and established RA at month 24. *p

Patients with RA on csDMARDs with and without GC, bDMARDs/tofacitinib with and without GC on the x axis. Patients with RA on csDMARDs with and without.

Adjusted estimates of DAS28 (95% CI) and RAPID3 (95% CI) scores over time based on multivariate models a priori adjusted for possible confounders: age,

Percentage of patients with RA achieving DAS28(CRP)<2

JSN and SvdH damage and progression scores with and without the CMC3-5 joints. JSN and SvdH damage and progression scores with and without the CMC3-5 joints.

Cox proportional-hazards model of time to first RA flare after treatment withdrawal for patients who entered the re-treatment period (n=146). Cox proportional-hazards.

Mean Short-Form 36 (SF-36) domain scores at baseline and 6 months in patients receiving active or placebo corticosteroids, cDMARDs or TNFis. Mean Short-Form.

Percentage of patients achieving 20% improvement in the American College of Rheumatology criteria at week 12 by patient demographic and disease characteristics.

The thickness of the subchondral bone plate for healthy subjects and patients with osteoarthritis (OA). The thickness of the subchondral bone plate for.

Serum sRANKL and OPG levels in healthy donors and patients with RA at baseline and after MTX and low-dose prednisolone treatment. Serum sRANKL and OPG.

Frequency of methotrexate (MTX) doses at 24 months (plot) and summary of MTX doses across the MTX dosing categories (low, medium, high) based on data at.

Ultrasonographic characteristics and synovitis pattern of patients with inflammatory bowel disease (IBD) with onset of peripheral arthritis under tumour.

Patient disposition after 2 years of treatment.

Study design. *Randomisation stratified by corticosteroid use at baseline. Study design. *Randomisation stratified by corticosteroid use at baseline. DAS28-CRP,

Satisfaction with control of RA

SIR data for all CZP-treated patients (RCT+OLE) for each malignancy type, standardised to the general population by age and gender (GLOBOCAN and SEER).

Schematic depiction of categories of inflammation in 350 small joints during progression from clinically suspect arthralgiato inflammatory arthritis. Schematic.

Classification tree with the selected characteristics.

Cardiovascular disease risk assessment capture rates in the NOCAR project, evaluated across diagnosis groups and participating centre. Cardiovascular disease.

Patient-level radiographic progression of structural joint damage at year 1 and year 2 by original randomisation. Patient-level radiographic progression.

(A) Mean NMR spectra of patient sera show differences in metabolite intensities between responders and non-responders before (a) and 6 months after (b)

Joint pain location and severity.

Nail photographs and MRI scans of a patient with psoriatic arthritis.

Forest plot showing the results of the meta-analysis on the effect of strength exercise on M.quadriceps femoris in people with rheumatoid arthritis and.

Forest plot showing the results of the meta-analysis on the effect of aerobic exercise on measured on VO2max in people with rheumatoid arthritis, spondyloarthritis.

Depiction of bone marrow oedema using different techniques

Graphical representation of the content of the Social Role Participation Questionnaire (SRPQ), which assesses several dimensions of role participation.

ACPA and RF titres in patients with early RA treated with abatacept+MTX compared with MTX alone. ACPA and RF titres in patients with early RA treated with.

Percent of patients with ASDAS inactive disease grouped by normal or elevated CRP at baseline through week 156. §p

Improvement in BASDAI score in patients with normal or elevated CRP at baseline through week 156. *p

WOMAC (Western Ontario and McMaster Universities Arthritis Index) symptoms in the operated knee and contralateral knee over time and by treatment. WOMAC.

Percentage of patients achieving remission by conversion to ACPA seronegative status. Percentage of patients achieving remission by conversion to ACPA.

Multivariate Cox proportional hazards model of time to first serious infectious events. Multivariate Cox proportional hazards model of time to first serious.

Changes in non-classical (CD11b+CD14+CD163−CD16+) and classical (CD11b+CD14+CD163+CD16−) monocytes over time in patients with rheumatoid arthritis (RA)

Kaplan-Meier failure curves with development of RA stratified by depression exposure. Kaplan-Meier failure curves with development of RA stratified by.

Fig. 1 Anti-LtxA antibody concentrations in various patient groups.

Distribution of points (%) across the ESSDAI domains in patients with neurological involvement and in those with non-neurological systemic involvement.

Presentation transcript:

Fatigue severity across early patients with arthritis with different diagnoses at disease onset (A) and over 3 years of disease (B). Fatigue severity across early patients with arthritis with different diagnoses at disease onset (A) and over 3 years of disease (B). (A) Presented are medians and IQRs of fatigue severity at disease onset. The data of rheumatoid arthritis (RA) are presented in bold. An asterisk indicates a significant different fatigue level compared to RA when adjusted for age and gender. The numbers of patients at baseline are 902 for RA, 73 for SCTD, 48 for RS3PE, 96 for reactive arthritis, 19 for paramalignant arthritis, 65 for sarcoidosis, 25 for others, 126 for inflammatory OA, 13 for lyme arthritis, 706 for UA, 271 for PsA/SpA, 90 for (pseudo)gout, four for septic arthritis and four for post-traumatic joint swelling. (B) Presented are medians of fatigue severity over 3 years of disease. Available, unmodelled data without imputation of missing data is depicted. The numbers of available fatigue data per diagnosis at baseline, one, 2 and 3 years follow-up were respectively: 73, 32, 25 and 21 for SCTD; 902, 537, 411 and 432 for RA; 706, 270, 155 and 139 for UA; 271, 151, 110, 101 for PsA/SpA; 90, 13, 4 and 2 for (pseudo)gout. SCTD, systemic connective tissue disease; RS3PE, remitting seronegative symmetrical synovitis with pitting edema; RA, rheumatoid arthritis; OA, osteoarthritis; UA, undifferentiated arthritis; PsA, psoriatic arthritis; SpA, spondylarthropathy with peripheral arthritis. Hanna W van Steenbergen et al. RMD Open 2015;1:e000041 Copyright © BMJ Publishing Group & EULAR. All rights reserved.